01 January 1996
Med Sci Monit 1996; 2(1): CR82-84 :: ID: 499527
The aim of this open clinical trial was to evaluate the clinical efficacy of fusafungine (Bioparox Servier) in patients with upper respiratory infections. Patients and method: Twenty-one consecutive patients with upper respiratory tract infections were treated with fusafungine administered locally in four daily doses over seven days. The patients were volunteers and gave informed consent to participation in the clinical trial. Results: Good or very good results of treatment were observed in more than 60% of the patients. Fusafungine may be used as an effective alternative or an adjuvant to systemic antibiotic treatment in upper respiratory infections.
Keywords: fusafungine, clinical efficacy, upper respiratory infections
Most Viewed Current Articles
13 Apr 2020 : Original articleOutcome of 24 Weeks of Combined Schroth and Pilates Exercises on Cobb Angle, Angle of Trunk Rotation, Chest...
Med Sci Monit Basic Res 2020; 26:e920449
11 May 2020 : Original articleAnalysis of Psychological and Sleep Status and Exercise Rehabilitation of Front-Line Clinical Staff in the ...
Med Sci Monit Basic Res 2020; 26:e924085
05 Jan 2021 : Review articleA Southeast Asian Perspective on the COVID-19 Pandemic: Hemoglobin E (HbE)-Trait Confers Resistance Against...
Med Sci Monit Basic Res 2021; 27:e929207
10 Aug 2020 : Clinical ResearchEffects of Cognitive Task Training on Dynamic Balance and Gait of Patients with Stroke: A Preliminary Rando...
Med Sci Monit Basic Res 2020; 26:e925264